Bolda-Med 300mg/ml 10ml Vial by Bioniche Pharma

Usage

1. Before opening the vial, cross-reference the printed batch number against Bioniche Pharma's released HPLC chromatogram and LAL endotoxin certificate to confirm the specific unit's analytical compliance.
2. Wipe the vial septum with a 70% isopropyl alcohol swab and allow a 30-second contact time before needle insertion — this step is especially relevant for a multi-dose vial accessed repeatedly over weeks.
3. Use a dedicated fill needle (18–21 gauge) to draw the correct volume; at 300 mg/ml, each 0.1 ml on a 3 ml syringe equals 30 mg — verify the drawn volume against your target dose before swapping to the injection needle.
4. Administer intramuscularly into a large muscle group (gluteus medius, vastus lateralis) using a 23–25 gauge injection needle; rotate sites across the weekly injection schedule to reduce cumulative tissue stress.
5. After each draw, refrigerate the vial at 2–8 °C; inspect the solution for cloudiness, discolouration, or particulates before every subsequent use — any visible change warrants vial discard regardless of remaining volume.
6. Record the date of each injection and the batch number in a cycle log; this documentation enables precise correlation between dose timing and blood-panel results when haematocrit or lipid values are reviewed mid-cycle.

Warnings

Frequently asked questions

What does finished-product HPLC verification mean for Bolda-Med 300mg/ml?

Finished-product HPLC means the sealed vial itself — not just the raw API — is analysed by high-performance liquid chromatography to confirm the stated 300 mg/ml concentration. The chromatogram separates boldenone undecylenate from impurities by retention time and UV absorbance, producing a quantitative potency figure that is batch-traceable and independent of supplier documentation.

How does the LAL endotoxin test protect users of an injectable boldenone product?

The LAL (Limulus Amebocyte Lysate) assay detects gram-negative bacterial endotoxins at picogram-per-millilitre sensitivity, a level aligned with pharmacopoeial standards for injectable drugs (USP <85>). Endotoxins are the primary cause of post-injection pyrogenic reactions. A batch that clears the LAL threshold carries a measurable, method-backed sterility marker that visual inspection cannot provide.

How is HPLC-based purity testing different from a raw-material Certificate of Analysis?

A raw-material CoA verifies the API's purity before manufacturing; HPLC on the finished product confirms concentration integrity survived compounding, sterile filtration, and vial filling. These are two separate quality checkpoints. Only finished-product HPLC tells you what is quantifiably present in the vial you inject, making it the more directly relevant assay for the end user.

How should Bolda-Med 10ml vials be stored after first use to maintain sterility?

After the septum is first punctured, store the vial at 2–8 °C (refrigerated) and use a fresh sterile needle for every subsequent draw. Bioniche Pharma's multi-benzyl-alcohol preserved formulation supports multi-dose use, but refrigeration slows microbial growth between draws. Discard the vial if the solution becomes cloudy, discoloured, or if particulates are visible.

What syringe and draw technique is recommended for accurate dosing from a 300mg/ml vial?

A standard 3 ml luer-lock syringe with 0.1 ml graduations gives 30 mg dose resolution per mark at 300 mg/ml. For doses below 150 mg, a 1 ml syringe with finer graduations reduces measurement error. Always draw with a wider-gauge fill needle, then swap to the injection needle before administration to minimise dead-space volume loss and maintain accurate dosing. (2) angle_used

Manufacturer

Bioniche Pharma is a pharmaceutical manufacturer that established its market presence with a documentation-first production model, positioning independently verifiable analytical data — specifically finished-product HPLC chromatograms and batch-level LAL endotoxin records — as the primary commercial differentiator. The company's manufacturing infrastructure is structured around GMP-aligned quality control checkpoints applied at the finished-product stage, a process architecture that distinguishes it from brands whose quality assurance relies solely on API supplier documentation. Bolda-Med 300 mg/ml represents Bioniche Pharma's boldenone undecylenate entry in the analytically documented injectable segment.